Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07092254 · ClinicalTrials.gov registry record
Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer
A clinical trial of Triple Negative Breast Cancer, sponsored by Daiichi Sankyo.
- Active
- Registry status
- 760
- Enrollment target
- 1
- Study location
NCT07092254 is a study of Triple Negative Breast Cancer that is active but no longer recruiting, run by Daiichi Sankyo. The registered enrollment target is 760 participants, above the 240-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (217% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07092254, a study of Triple Negative Breast Cancer, is active but no longer recruiting, sponsored by Daiichi Sankyo.
- ACTIVE NOT RECRUITING
- Registry status
- 760 participants
- Enrollment target
- 1
- Study location
Study Summary
This transnational noninterventional study aims to gather real-world evidence on locally recurrent inoperable (hereafter referred to as advanced) or metastatic TNBC (a/m TNBC) biomarker testing, treatment patterns by line of therapy, and outcomes to contextualize findings of TROPION-Breast02 and TROPION-Breast05 in selected settings outside the United States (US), including Canada, the United Kingdom (UK), France, and Spain.
Conditions Studied
Interventions
- DRUG No drug
Study Locations (1)
New Jersey
- Research Site - Basking Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 760 participants |
| Start Date | 2025-09-01 |
| Est. Completion | 2026-06-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07092254
The ClinicalTrials.gov registry entry for NCT07092254 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 760 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 240-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (217% higher). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Triple Negative Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which No drug is the first listed.
NCT07092254 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT07092254 about?
NCT07092254 is a clinical study titled "Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer". This transnational noninterventional study aims to gather real-world evidence on locally recurrent inoperable (hereafter referred to as advanced) or metastatic TNBC (a/m TNBC) biomarker testing, treatment patterns by line of therapy, and outcomes to contextualize findings of TROPION-Breast02 and TRO...
What is the current status of trial NCT07092254?
This trial is currently active not recruiting. The enrollment target is 760 participants. The study started on 2025-09-01. Estimated completion is 2026-06-12.
What conditions does trial NCT07092254 study?
This clinical trial studies the following conditions: Triple Negative Breast Cancer.
What interventions are being tested in trial NCT07092254?
The interventions under investigation include: No drug (DRUG).
Who is sponsoring clinical trial NCT07092254?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07092254 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Triple Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients
RECRUITING · Phase 2
-
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.